Milestone Pharmaceuticals

General Information


We are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker that we designed and are developing as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT, as they occur. PSVT is a rapid heart rate condition that starts and stops without warning, often experienced by patients with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting or anxiety.

Employees: 23
Founded: 2003
Contact Information
Address 1111 Dr. Frederik-Philips Blvd., Suite 420, Montréal, Québec, Canada H4M 2X6
Phone Number (514) 336-0444
Web Address
View Prospectus: Milestone Pharmaceuticals
Financial Information
Market Cap $354.7mil
Revenues $0 mil (last 12 months)
Net Income $-23.2 mil (last 12 months)
IPO Profile
Symbol MIST
Exchange NASDAQ
Shares (millions): 5.5
Price range $15.00 - $15.00
Est. $ Volume $82.5 mil
Manager / Joint Managers Jefferies/ Cowen and Company/ Piper Jaffray
CO-Managers Oppenheimer & Co.
Expected To Trade: 5/9/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change